Daiichi Sankyo Enters Agreement with Heptares Therapeutics to Discover and Develop Novel, Small-Mole

Daiichi Sankyo press release ------ Daiichi Sankyo Company, Limited (hereafter “Daiichi Sankyo”) announces that it has entered with Heptares Therapeutics Limited (location: Hertfordshire, UK, hereafter “Heptares”), a wholly owned subsidiary of Sosei Group Corporation, into a drug discovery and licensing agreement focused on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain. Under the terms of the agreement, Heptares will apply its proprietary StaR® (stabilised receptor) technology to engineer thermally stabilised forms of the GPCR as the basis for the drug discovery programme. Heptares will also employ advanced structural biology and rational drug design approaches, X-ray crystallography and fragment screening to delineate the GPCR's structure and to generate lead candidates. Daiichi Sankyo will also participate in lead generation and in vivo models. To get more in depth information click on the picture below to read the release.